(0.22%) 5 142.75 points
(0.16%) 38 504 points
(0.32%) 17 903 points
(-0.55%) $83.39
(1.92%) $1.960
(0.08%) $2 349.10
(0.27%) $27.61
(0.74%) $928.95
(-0.22%) $0.933
(-0.29%) $10.99
(-0.33%) $0.798
(1.36%) $93.12
Live Chart Being Loaded With Signals
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies...
Stats | |
---|---|
Šios dienos apimtis | 36 599.00 |
Vidutinė apimtis | 12 804.00 |
Rinkos kapitalizacija | 25.23B |
Last Dividend | $0.726 ( 2023-05-01 ) |
Next Dividend | $0 ( N/A ) |
P/E | 70.72 |
ATR14 | $0.189 (0.28%) |
UCB SA Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
UCB SA Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $5.25B |
Bruto pelnas: | $3.55B (67.50 %) |
EPS: | $1.810 |
FY | 2023 |
Pajamos: | $5.25B |
Bruto pelnas: | $3.55B (67.50 %) |
EPS: | $1.810 |
FY | 2022 |
Pajamos: | $5.52B |
Bruto pelnas: | $3.84B (69.64 %) |
EPS: | $2.20 |
FY | 2021 |
Pajamos: | $5.78B |
Bruto pelnas: | $4.34B (75.11 %) |
EPS: | $5.60 |
Financial Reports:
No articles found.
UCB SA Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0.726 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.663 | 2013-05-02 |
Last Dividend | $0.726 | 2023-05-01 |
Next Dividend | $0 | N/A |
Payout Date | 2023-05-18 | |
Next Payout Date | N/A | |
# dividends | 11 | -- |
Total Paid Out | $7.46 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.23 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.90 | |
Div. Directional Score | 8.72 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
DWNX | Ex Dividend Knight | 2023-09-28 | Quarterly | 0 | 0.00% | |
TYFG | Ex Dividend Junior | 2023-09-28 | Quarterly | 0 | 0.00% | |
JRONY | Ex Dividend Knight | 2023-05-15 | Annually | 0 | 0.00% | |
BPOSY | Ex Dividend Knight | 2023-05-18 | Annually | 0 | 0.00% | |
RMYHY | Ex Dividend Knight | 2023-09-05 | Semi-Annually | 0 | 0.00% | |
FCELB | Ex Dividend Junior | 2023-07-31 | Semi-Annually | 0 | 0.00% | |
VWAPY | Ex Dividend Junior | 2023-05-11 | Annually | 0 | 0.00% | |
LRENY | Ex Dividend Knight | 2023-06-30 | Quarterly | 0 | 0.00% | |
CKNQP | Ex Dividend Junior | 2023-09-14 | Quarterly | 0 | 0.00% | |
SKHHY | Ex Dividend Knight | 2023-09-05 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0656 | 1.500 | 8.69 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0331 | 1.200 | 8.90 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0571 | 1.500 | -0.477 | -0.715 | [0.1 - 1] |
payoutRatioTTM | 0.490 | -1.000 | 5.10 | -5.10 | [0 - 1] |
currentRatioTTM | 1.317 | 0.800 | 8.42 | 6.73 | [1 - 3] |
quickRatioTTM | 0.839 | 0.800 | 9.77 | 7.81 | [0.8 - 2.5] |
cashRatioTTM | 0.329 | 1.500 | 9.28 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.196 | -1.500 | 6.74 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 4.50 | 1.000 | 9.45 | 9.45 | [3 - 30] |
operatingCashFlowPerShareTTM | 5.26 | 2.00 | 8.25 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 2.96 | 2.00 | 8.52 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.338 | -1.500 | 8.65 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.648 | 1.000 | 2.54 | 2.54 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.120 | 1.000 | 9.59 | 9.59 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.328 | 1.000 | 9.29 | 9.29 | [0.2 - 2] |
assetTurnoverTTM | 0.505 | 0.800 | 9.97 | 7.97 | [0.5 - 2] |
Total Score | 12.54 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 22.86 | 1.000 | 7.79 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0571 | 2.50 | -0.306 | -0.715 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 2.96 | 2.00 | 9.01 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.34 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 5.26 | 2.00 | 8.25 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.490 | 1.500 | 5.10 | -5.10 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.127 | 1.000 | 9.32 | 0 | [0.1 - 0.5] |
Total Score | 4.90 |
UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.